Top

Published in:

Open Access 01-02-2016 | Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)

Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Author: Sten Nilsson

Published in: Current Oncology Reports | Issue 2/2016

Abstract

Metastatic castration-resistant prostate cancer (mCRPC) frequently metastasizes to the bone, often resulting in painful skeletal events, reduced quality of life, and reduced survival. The beta-emitting radiopharmaceuticals strontium-89 and samarium-153 alleviated pain in mCRPC patients with widespread skeletal metastases and have been associated with myelotoxicity. Radium-223, a first-in-class alpha-emitting radiopharmaceutical, prolonged overall survival, delayed symptomatic skeletal events, and improved quality of life, versus placebo, in patients with CRPC and symptomatic bone metastases and no visceral metastases. Radium-223 provided survival benefit to patients with CRPC and symptomatic bone metastases, regardless of prior docetaxel use. Importantly, prostate-specific antigen level and pain palliation were not a measure of radium-223 treatment response and should not alter the decision to administer all six radium-223 injections, the recommended regimen for survival benefit. Radium-223 was generally well tolerated, leading to ongoing clinical trials in combination with other therapeutics. Thus, radium-223 is a valuable addition to the mCRPC treatment armamentarium.

Sharifi N, Dahut WL, Steinberg SM, Figg WD, Tarassoff C, Arlen P, et al. A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int. 2005;96(7):985–9. doi:10.1111/j.1464-410X.2005.05798.x.CrossRefPubMed

Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31(5):578–83.CrossRefPubMed

DePuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP, Saad F. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer. 2007;15(7):869–76. doi:10.1007/s00520-006-0203-x.CrossRefPubMed

Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 2002;168(3):1005–7. doi:10.1097/01.ju.0000024395.86788.cc.CrossRefPubMed

Coleman R, Brown J, Terpos E, Lipton A, Smith MR, Cook R, et al. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev. 2008;34(7):629–39. doi:10.1016/j.ctrv.2008.05.001.PubMedCentralCrossRefPubMed

Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20. doi:10.1056/NEJMoa041318.CrossRefPubMed

Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12. doi:10.1056/NEJMoa040720.CrossRefPubMed

Attard G, Parker C, Eeles RA, Schroder F, Tomlins SA, Tannock I, et al. Prostate cancer. Lancet. 2015. doi:10.1016/S0140-6736(14)61947-4.

Brady D, Parker C, O'Sullivan JM. Bone-targeting radiopharmaceuticals including radium-223. Cancer J. 2013;19(1):71–8.CrossRefPubMed

10.

NCCN Clinical Practice Guidelines in Oncology: prostate cancer—version 1.2015. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines_nojava.asp.

11.

Parker C, Gillessen S, Heidenreich A, Horwich A. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v69–77. doi:10.1093/annonc/mdv222.CrossRefPubMed

12.••

Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23. doi:10.1056/NEJMoa1213755. This article reports the results of the landmark phase 3 ALSYMPCA study of radium-223, a first-in-class radiopharmaceutical in metastatic castration-resistant prostate cancer. Primary efficacy (overall survival), main secondary efficacy end point results, and important safety data presented here showed that radium-223 was well tolerated and provided a survival benefit to mCRPC patients. CrossRefPubMed

13.

Bruland OS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006;12(20 Pt 2):6250s–7s. doi:10.1158/1078-0432.CCR-06-0841.CrossRefPubMed

14.

Henriksen G, Breistol K, Bruland OS, Fodstad O, Larsen RH. Significant antitumor effect from bone-seeking, alpha-particle-emitting 223Ra demonstrated in an experimental skeletal metastases model. Cancer Res. 2002;62(11):3120–5.PubMed

15.

Henriksen G, Fisher DR, Roeske JC, Bruland OS, Larsen RH. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med. 2003;44(2):252–9.PubMed

16.

Suominen MI, Rissanen JP, Kakonen R, Fagerlund KM, Alhoniemi E, Mumberg D, et al. Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis. J Natl Cancer Inst. 2013;105(12):908–16. doi:10.1093/jnci/djt116.CrossRefPubMed

17.

Lewington VJ, McEwan AJ, Ackery DM, Bayly RJ, Keeling DH, Macleod PM, et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer. 1991;27(8):954–8.CrossRefPubMed

18.

Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25(5):805–13.CrossRefPubMed

19.

Metastron (strontium-89 chloride) [prescribing information]. Buckinghamshire UK; GE Healthcare Limited. Available at: http://www.old.health.gov.il/units/pharmacy/trufot/alonim/Metastron_dr_1326962307309.pdf.

20.

US Food and Drug Administration. US Department of Health and Human Services. Available at: http://www.fda.gov.

21.

Saad F, Chi KN, Finelli A, Hotte SJ, Izawa J, Kapoor A, et al. The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC). Can Urol Assoc J. 2015;9(3–4):90–6. doi:10.5489/cuaj.2526.PubMedCentralCrossRefPubMed

22.

Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63(5):940–5. doi:10.1016/j.urology.2004.01.034.CrossRefPubMed

23.

Quadramet technical user’s guide. Quadramet (samarium Sm 153 lexidronam injection). Vancouver, BC; Superna Life Sciences. http://www.quadrametcanada.com/pdf/medical/clinic/Quadramet%20users%20guide-Superna%20Ordering.pdf.

24.

D'Angelo G, Sciuto R, Salvatori M, Sperduti I, Mantini G, Maini CL, et al. Targeted “bone-seeking” radiopharmaceuticals for palliative treatment of bone metastases: a systematic review and meta-analysis. Q J Nucl Med Mol Imaging. 2012;56(6):538–43.PubMed

25.

Collins C, Eary JF, Donaldson G, Vernon C, Bush NE, Petersdorf S, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med. 1993;34(11):1839–44.PubMed

26.

Nilsson S, Strang P, Aksnes AK, Franzen L, Olivier P, Pecking A, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 2012;48(5):678–86. doi:10.1016/j.ejca.2011.12.023.CrossRefPubMed

27.

Sartor O, Reid RH, Bushnell DL, Quick DP, Ell PJ. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer. 2007;109(3):637–43. doi:10.1002/cncr.22431.CrossRefPubMed

28.

Kasalicky J, Krajska V. The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases. Eur J Nucl Med. 1998;25(10):1362–7.CrossRefPubMed

29.

James ND, Pirrie S, Barton D, Brown JE, Billingham L, Collins SI et al. Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747). J Clin Oncol. 2013;31(suppl):Abstract LBA5000.

30.

Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001;357(9253):336–41. doi:10.1016/S0140-6736(00)03639-4.CrossRefPubMed

31.

Amato RJ, Hernandez-McClain J, Henary H. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer. Am J Clin Oncol. 2008;31(6):532–8. doi:10.1097/COC.0b013e318172aa92.CrossRefPubMed

32.

Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27(10):1564–71. doi:10.1200/JCO.2008.19.2146.CrossRefPubMed

33.

Heron DE, Brufsky A, Beriwal S, Kurman M. Myelotoxicity of samarium Sm 153 lexidronam in patients receiving prior treatment with chemotherapy or radiotherapy. Ann Oncol. 2008;19(9):1639–43. doi:10.1093/annonc/mdn178.CrossRefPubMed

34.

Baczyk M, Milecki P, Pisarek M, Gut P, Antczak A, Hrab M. A prospective randomized trial: a comparison of the analgesic effect and toxicity of 153Sm radioisotope treatment in monotherapy and combined therapy including local external beam radiotherapy (EBRT) among metastatic castrate resistance prostate cancer (mCRPC) patients with painful bone metastases. Neoplasma. 2013;60(3):328–33. doi:10.4149/neo_2013_044.CrossRefPubMed

35.

Heianna J, Toita T, Endo W, Kasuya G, Ariga T, Hashimoto S, et al. Concurrent use of strontium-89 with external beam radiotherapy for multiple bone metastases: early experience. Ann Nucl Med. 2015;29:848–53. doi:10.1007/s12149-015-1010-6.

36.

Nilsson S, Larsen RH, Fossa SD, Balteskard L, Borch KW, Westlin JE, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11(12):4451–9. doi:10.1158/1078-0432.CCR-04-2244.CrossRefPubMed

37.

Nilsson S, Franzen L, Parker C, Tyrrell C, Blom R, Tennvall J, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8(7):587–94. doi:10.1016/S1470-2045(07)70147-X.CrossRefPubMed

38.

Xofigo (radium Ra 223 dichloride) injection, for intravenous use [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals; 2013. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203971lbl.pdf.

39.

Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, et al. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Eur J Cancer. 2014;50(9):1617–27. doi:10.1016/j.ejca.2014.03.010.CrossRefPubMed

40.

Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol. 2015;26(8):1547–73. doi:10.1093/annonc/mdv249.CrossRefPubMed

41.

Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458–68.CrossRefPubMed

42.

Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813–22. doi:10.1016/S0140-6736(10)62344-6.PubMedCentralCrossRefPubMed

43.•

Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15(7):738–46. doi:10.1016/s1470-2045(14)70183-4. This article presents symptomatic skeletal event data from the phase 3 ALSYMPCA trial of radium-223 in CRPC patients with symptomatic skeletal metastases.CrossRefPubMed

44.

Sonpavde G, Pond GR, Berry WR, de Wit R, Armstrong AJ, Eisenberger MA, et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol. 2012;30(5):607–13. doi:10.1016/j.urolonc.2010.07.002.CrossRefPubMed

45.

Wymenga LF, Boomsma JH, Groenier K, Piers DA, Mensink HJ. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase. BJU Int. 2001;88(3):226–30.CrossRefPubMed

46.

Heinrich D, Parker C, Shan M, Wilhelm S, Garcia-Vargas J, O'Bryan-Tear CG, et al. Effects of radium-223 dichloride (Ra-223) on total alkaline phosphatase (ALP) and prostate-specific antigen (PSA) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA trial. Eur Urol. 2014;13(suppl):e865. Abstract 865.

47.

Cislo P, Sartor O, Reuning-Scherer J, Shan M, Zhan L, Parker C. Effects of radium-223 dichloride (ra-223) on health-related quality of life (HRQoL) assessed by the EQ-5D utility scores in ALSYMPCA. Eur Urol. 2015;14(suppl 2):e673-ea. Abstract 673.

48.

Nilsson S, Tomblyn M, Cislo P, Reuning-Scherer J, Parker C. Patient-reported quality of life (QOL) analysis of radium-223 dichloride (Ra 223) evaluating pain relief from the phase 3 ALSYMPCA study. J Clin Oncol. 2014;32(5s suppl):Abstract 5069.

49.

ClinicalTrials.gov. National Institutes of Health. Available at: https://clinicaltrials.gov/.

50.

Nilsson S. Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety. Expert Opin Drug Saf. 2015;14(7):1127–36. doi:10.1517/14740338.2015.1045874.CrossRefPubMed

51.

Sartor O, Fernandez DC, Morris MJ, Iagaru A, Brown A, Almeida F, et al. Prior and concurrent use of abiraterone and enzalutamide with Ra-223 in an expanded access setting. J Clin Oncol. 2015;33(suppl 7):Abstract 253. Available at: http://meetinglibrary.asco.org/content/141678-159.

52.

Sartor O, Coleman RE, Nilsson S, Vogelzang NJ, Staudacher K, Thuresson M, et al. 3-year follow-up of chemotherapy following radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients (Pts) with symptomatic bone metastases (Mets) from ALSYMPCA. Presentation at: European Society for Medical Oncology; September 25–29, 2015; Vienna, Austria. Abstract 2510. Available at: http://www.europeancancercongress.org/Scientific-Programme/Searchable-Programme#anchorScpr. 2015.

53.

Parker C, Vogelzang NJ, Sartor O, Coleman RE, Fang F, Skjorestad I, et al. 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA. J Clin Oncol. 2015;33(suppl 7):Abstract 195. Available at: http://meetinglibrary.asco.org/content/141454-159.

54.

Finkelstein SE, Michalski JM, O'Sullivan JM, Parker C, Garcia-Vargas JE, Sartor O. External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial. J Clin Oncol. 2015;33(suppl 7):Abstract 182. Available at: http://meetinglibrary.asco.org/content/141151-159.

55.•

Hoskin P, Sartor O, ÓSullivan JM, Johannessen DC, Helle SI, Logue J, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15(12):1397–406. doi:10.1016/s1470-2045(14)70474-7. This article presents prespecified docetaxel subgroup analyses from the phase 3 ALSYMPCA trial that were designed to assess the effect of previous use or nonuse of docetaxel on the efficacy and safety of radium-223 in mCRPC patients.CrossRefPubMed

56.

Sartor O, Coleman R, Nilsson S, Vogelzang NJ, Staudacher K, Thuresson M et al. 3-year follow-up of chemotherapy following radium223 dichloride (Ra223) in castration-resistant prostate cancer (CRPC) patients (Pts) with symptomatic bone metastases (Mets) from ALSYMPCA. 2015:e2510-ea. Abstract 2510.

57.

Morris MJ, Higano CS, Scher HI, Sweeney C, Antonarakis ES, Shevrin DH, et al. Effects of radium-223 dichloride (Ra-223) with docetaxel (D) vs D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): a phase 1/2a clinical trial. J Clin Oncol. 2015;33(suppl):Abstract 5012. Available at: http://meetinglibrary.asco.org/content/152183-156.

58.

Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol. 2004;164(1):217–27. doi:10.1016/S0002-9440(10)63112-4.PubMedCentralCrossRefPubMed

59.

Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 1995;9(4):401–6. doi:10.1038/ng0495-401.CrossRefPubMed

60.

de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005. doi:10.1056/NEJMoa1014618.PubMedCentralCrossRefPubMed

61.

Ryan CJ, Molina A, Griffin T. Abiraterone in metastatic prostate cancer. N Engl J Med. 2013;368(15):1458–9. doi:10.1056/NEJMc1301594.PubMed

62.

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97. doi:10.1056/NEJMoa1207506.CrossRefPubMed

63.

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–33. doi:10.1056/NEJMoa1405095.PubMedCentralCrossRefPubMed

64.

Vogelzang NJ, Fernandez DC, Morris MJ, Iagaru A, Brown A, Almeida F, et al. Radium-223 dichloride (Ra-223) in U.S. expanded access program (EAP). J Clin Oncol. 2015;33(suppl 7):Abstract 247. Available at: http://meetinglibrary.asco.org/content/141865-159.

65.

O'Sullivan J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, Lévy J, et al. Effects of concomitant use of abiraterone and/or enzalutamide with radium-223 on safety and overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients treated in an international early access program (EAP). Presentation at: European Society for Medical Oncology; September 25–29, 2015; Vienna, Austria. Abstract 2561. Available at: http://www.europeancancercongress.org/Scientific-Programme/Searchable-Programme#anchorScpr. 2015.

66.

Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 2005;6(6):392–400. doi:10.1016/S1470-2045(05)70206-0.CrossRefPubMed

Title: Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
Author: Sten Nilsson
Publication date: 01-02-2016
Publisher: Springer US
Published in: Current Oncology Reports / Issue 2/2016
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-015-0495-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2016

The Role of Narrow Band Imaging in Head and Neck Cancers

Advances in Local and Systemic Therapies for Hepatocellular Cancer

Impact of Body Weight and Body Composition on Ovarian Cancer Prognosis

Advances in the Management of Gastric and Gastroesophageal Cancers

Clinically Relevant Physical Benefits of Exercise Interventions in Breast Cancer Survivors

Communication About Sexuality in Advanced Illness Aligns With a Palliative Care Approach to Patient-Centered Care

Keynote webinar | Spotlight on antibody–drug conjugates in cancer